Loading...
Docoh

Amarin (AMRN)

Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its scientific research foundation to its focus on clinical trials, and now its commercial expansion, it is evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. It is committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

Company profile

Ticker
AMRN
Exchange
CEO
John Thero
Employees
Incorporated
Location
Fiscal year end
Former names
AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC
SEC CIK
Subsidiaries
Amarin Pharmaceuticals Ireland Limited • Amarin Pharma, Inc. • Ester Neurosciences Limited • Amarin Switzerland GmbH • Amarin Germany GmbH • Amarin France SAS • Amarin UK Limited • Amarin Belgium, branch of Amarin Switzerland GmbH • Amarin Denmark, filial af Amarin Switzerland GmbH • Amarin Switzerland GmbH ...

AMRN stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

3 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 228M 228M 228M 228M 228M 228M
Cash burn (monthly) (no burn) 8.25M 21.6M 7.49M 21.53M 16.35M
Cash used (since last report) n/a 11.82M 30.93M 10.72M 30.83M 23.42M
Cash remaining n/a 216.18M 197.07M 217.28M 197.17M 204.58M
Runway (months of cash) n/a 26.2 9.1 29.0 9.2 12.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Michael Wayne Kalb Ordinary Shares Payment of exercise Dispose F No No 1.33 29,682 39.48K 337,314
29 Jul 22 Michael Wayne Kalb Ordinary Shares Payment of exercise Dispose F No No 1.33 17,220 22.9K 284,662
29 Jul 22 Michael Wayne Kalb Ordinary Shares Option exercise Acquire M No No 0 47,767 0 301,882
29 Jul 22 Michael Wayne Kalb RSU Ordinary Shares Option exercise Dispose M No No 0 47,767 0 95,533
29 Jul 22 Aaron Berg Ordinary Shares Payment of exercise Dispose F No No 1.33 8,181 10.88K 411,155
29 Jul 22 Aaron Berg Ordinary Shares Option exercise Acquire M No No 0 23,884 0 419,336
29 Jul 22 Aaron Berg RSU Ordinary Shares Option exercise Dispose M No No 0 23,884 0 47,766
29 Jul 22 Steven B Ketchum Ordinary Shares Payment of exercise Dispose F No No 1.33 8,181 10.88K 512,615
29 Jul 22 Steven B Ketchum Ordinary Shares Option exercise Acquire M No No 0 23,884 0 520,796
29 Jul 22 Steven B Ketchum RSU Ordinary Shares Option exercise Dispose M No No 0 23,884 0 47,766
32.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 222 235 -5.5%
Opened positions 31 50 -38.0%
Closed positions 44 45 -2.2%
Increased positions 53 51 +3.9%
Reduced positions 51 60 -15.0%
13F shares Current Prev Q Change
Total value 424.01M 456.01M -7.0%
Total shares 127.76M 132.79M -3.8%
Total puts 2.71M 4.49M -39.6%
Total calls 1.22M 1.96M -37.8%
Total put/call ratio 2.2 2.3 -2.8%
Largest owners Shares Value Change
Sarissa Capital Management 24M $78.96M +24.7%
Baker Bros. Advisors 21.17M $69.65M 0.0%
Eversept Partners 8.98M $29.55M -15.1%
SCP Investment 6.75M $22.21M 0.0%
Avoro Capital Advisors 6M $19.74M 0.0%
Stonepine Capital Management 4.91M $16.16M NEW
Millennium Management 4.89M $16.07M +45.0%
Clearbridge Advisors 4.79M $15.76M +0.9%
MS Morgan Stanley 4.64M $15.26M -4.0%
Rock Springs Capital Management 4.42M $14.54M 0.0%
Largest transactions Shares Bought/sold Change
BVF 0 -16.46M EXIT
Stonepine Capital Management 4.91M +4.91M NEW
Sarissa Capital Management 24M +4.75M +24.7%
13D Management 2.02M +2.02M NEW
Eversept Partners 8.98M -1.59M -15.1%
Millennium Management 4.89M +1.52M +45.0%
Citadel Advisors 2.41M +1.21M +101.4%
Two Sigma Investments 2.06M +1.06M +106.5%
Anson Funds Management 0 -750K EXIT
Susquehanna International 912.18K -743.73K -44.9%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: amid, atherogenic, Brunswick, CCS, commodity, compromise, concordant, economy, elaborated, Excellence, fasting, FDC, geopolitical, German, impossible, intolerance, Intolerant, invasion, macroeconomic, magnify, military, NHS, NICE, Northwest, organizational, peripheral, pharmacologic, pro, prudent, rata, refining, relaxed, reorganization, Russia, stepwise, Ukraine, unsellable, unvested, voluntarily, workplace
Removed: advantage, ahead, anticipation, atherosclerotic, CDC, comparison, conference, consequentially, distracting, emphasize, enrolment, expertise, forward, fragile, fulfillment, gaining, heard, honor, improving, justified, litigate, maximize, medication, mitigated, objective, opted, ordering, outlined, prepare, proactive, reportedly, resumption, rightsized, scalable, summer, surprisingly, thousand, unfilled, unwilling, wait

Patents

Utility
Methods of Treating Mixed Dyslipidemia
4 Aug 22
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
Utility
Methods of treating mixed dyslipidemia
2 Aug 22
The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
Utility
Pharmaceutical Composition Comprising Eicosapentaenoic Acid and Nicotinic Acid and Methods of Using Same
9 Jun 22
The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders.
Utility
Methods of Treating Hypercholesterolemia
12 May 22
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of treating hypercholesterolemia, comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Utility
Methods of treating hypertriglyceridemia
5 Apr 22
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.